Should You Buy Eli Lilly and Co (LLY) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Eli Lilly (LLY) is currently not an optimal buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has strong financial performance and a promising pipeline, recent negative catalysts such as the FDA delay for orforglipron and insider selling activity suggest potential short-term headwinds. The technical indicators and options data also do not provide a strong bullish signal at this time. It is better to wait for further clarity on regulatory outcomes and market sentiment before considering entry.
Technical Analysis
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 49.003, showing no clear trend. Moving averages are converging, suggesting indecision in the market. Key support is at 1025.168, and resistance is at 1095.418. The stock is trading near its pivot level of 1060.293, indicating a lack of strong directional movement.
Analyst Ratings and Price Target Trends
Analysts maintain a positive outlook on Eli Lilly, with multiple Buy ratings and price targets ranging from $1,070 to $1,290. Analysts highlight the company's leadership in obesity and diabetes markets, as well as its strong execution and promising pipeline. However, recent updates reflect some caution due to regulatory delays and competitive risks.
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 1039.510
Current: 1039.510
